0.0004697949483226 0.00110539987840595 -0.000303984966561691 -0.00245951472945334 -0.0040899795501023 -0.00453213950146462 8.29049908803756E-05 0.00696401923395783
Sign Up Today X
Thanks for submitting the form.
Stockreport

Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio [Yahoo! Finance]

Biogen Inc. (BIIB)  More Company Research Source: Yahoo! Finance
Last biogen inc. earnings: 4/22 07:12 am Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
Biogen Inc (NASDAQ:BIIB, XETRA:IDP) will acquire Apellis Pharmaceuticals Inc (NASDAQ:APLS) for $41 per share in cash, in a deal valued at approximately $5.6 billion, it was announced on Tuesday. Apellis shareholders will also receive a nontransferable contingent value right (CVR) worth up to $4 per share if certain global sales milestones for SYFOVRE are achieved. Shares of Apellis surged more than 135% to about $40 on the news, while Biogen stock fell 5% to $178. The acquisition brings two approved complement C3 therapies—EMPAVELI for rare kidney diseases and SYFOVRE for geographic atrophy secondary to age-related macular degeneration—into Biogen's portfolio. In 2025, combined sales of the two products totaled $689 million, with mid-to-high teen growth expected at least through 2028. Biogen said the deal will expand its presence in immunology and rare disease and strengthen its nephrology franchise, particularly supporting the development of felzartamab, currently in Phase I [Read more]
IMPACT SNAPSHOT EVENT TIME: BIIB
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
BIIB alerts
from News Quantified
BIIB
NEWS
BIIB
Earnings
BIIB
Analyst Actions
BIIB
SEC Filings
Stockreport

Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio [Yahoo! Finance]

Biogen Inc.  (BIIB) 
More Company Research Source: Yahoo! Finance
Last biogen inc. earnings: 4/22 07:12 am Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
Biogen Inc (NASDAQ:BIIB, XETRA:IDP) will acquire Apellis Pharmaceuticals Inc (NASDAQ:APLS) for $41 per share in cash, in a deal valued at approximately $5.6 billion, it was announced on Tuesday. Apellis shareholders will also receive a nontransferable contingent value right (CVR) worth up to $4 per share if certain global sales milestones for SYFOVRE are achieved. Shares of Apellis surged more than 135% to about $40 on the news, while Biogen stock fell 5% to $178. The acquisition brings two approved complement C3 therapies—EMPAVELI for rare kidney diseases and SYFOVRE for geographic atrophy secondary to age-related macular degeneration—into Biogen's portfolio. In 2025, combined sales of the two products totaled $689 million, with mid-to-high teen growth expected at least through 2028. Biogen said the deal will expand its presence in immunology and rare disease and strengthen its nephrology franchise, particularly supporting the development of felzartamab, currently in Phase I [Read more]
IMPACT SNAPSHOT
EVENT TIME:
BIIB
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS